BCL-2 antisense therapy in patients with non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

Published:1997-04 Issue:9059 Volume:349 Page:1137-1141
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Webb A,Cunningham D,Cotter F,Clarke PA,Di Stefano F,Ross P,Corbo M,Dziewanowska Z

Publisher

Elsevier BV

Subject

General Medicine

Reference19 articles.

1. Bcl-2 is an inner mitochondrial memebrane protein that blocks programmed cell death;Hockenbery;Nature,1990

2. Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs;Miyashita;Cancer Res,1992

3. Prognostic significance of Bcl- 2 protein expression in aggressive non-Hodgkin's lymphoma: groupe d'etude des lymphomas de l'adulte (GELA);Hermine;Blood,1996

4. Prognostic significance of Bcl-2 expression and Bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British national lymphoma investigation study;Hill;Blood,1996

5. Evaluation of Bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma;Pezzella;Br J Cancer,1992

Cited by 457 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia;Seminars in Hematology;2024-04

2. Stargardt disease-associated in-frame ABCA4 exon 17 skipping results in significant ABCA4 function;Journal of Translational Medicine;2023-08-16

3. Pharmacologic Features of Drugs Targeting BCL 2 Family Members;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

4. Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2;Pharmaceutics;2022-01-01

5. Angelicin—A Furocoumarin Compound With Vast Biological Potential;Frontiers in Pharmacology;2020-04-16